The Lancet Neurology
Fecha de publicación: 1 de enero de 2022
Autores: Prof Charlotte E Teunissen, PhD , Inge M W Verberk, PhD, Elisabeth H Thijssen, PhD, Lisa Vermunt, PhD, Prof Oskar Hansson, PhD, Prof Henrik Zetterberg, PhD, Prof Wiesje M van der Flier, PhD, Prof Michelle M Mielke, PhD, Marta del Campo, PhD
DOI: https://doi.org/10.1016/S1474-4422(21)00361-6
Background: For many years, blood-based biomarkers for Alzheimer’s disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans
